Quick Answer
Cocrystal Pharma, Inc. reported Total Revenue of $2.01 million for fiscal year 2020.
Cocrystal Pharma, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $2.01M -69.3% |
| Revenue (ASC 606) | — | — | — | — | — | $2.01M -69.3% |
| Net Income | -$8.83M +49.5% |
-$17.50M +2.7% |
-$17.98M +53.7% |
-$38.84M -173.8% |
-$14.19M -47.0% |
-$9.65M +80.0% |
| Diluted EPS | -$0.78 +54.7% |
-$1.72 +8.0% |
-$1.87 +60.8% |
-$4.77 | — | — |
| Total Assets | $9.71M -27.8% |
$13.46M -57.0% |
$31.26M -23.5% |
$40.84M -48.6% |
$79.39M +46.4% |
$54.24M +90.1% |
| Cash and Equivalents | — | — | $26.35M -29.1% |
$37.14M -36.7% |
$58.70M +77.8% |
$33.01M +345.0% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $6.33M -33.5% |
$9.52M -63.9% |
$26.38M -33.4% |
$39.60M -48.9% |
$77.55M +47.7% |
$52.51M +104.2% |
| R&D Expense | $5.05M -59.7% |
$12.54M -17.4% |
$15.17M +22.4% |
$12.39M +40.9% |
$8.79M +45.7% |
$6.03M +50.7% |
| Operating Income | -$9.02M +49.6% |
-$17.88M +3.7% |
-$18.56M +52.2% |
-$38.83M -173.0% |
-$14.22M -48.4% |
-$9.59M +80.2% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 13.78M +35.5% |
10.17M +0.0% |
10.17M +24.9% |
8.14M +0.0% |
8.14M -88.4% |
70.44M +100.4% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2020 | $489.0K | -0.6% | -11.7% |
| Revenue (ASC 606) | September 30, 2020 | $489.0K | -0.6% | -11.7% |
| Net Income | September 30, 2025 | -$2.05M | +58.5% | +0.3% |
| Diluted EPS | September 30, 2025 | -$0.19 | +61.2% | +5.0% |
| Total Assets | September 30, 2025 | $10.45M | -35.6% | +22.8% |
| Cash and Equivalents | June 30, 2024 | $18.14M | -44.0% | -16.9% |
| Stockholders Equity | September 30, 2025 | $7.67M | -39.6% | +43.8% |
| R&D Expense | September 30, 2025 | $954.0K | -70.6% | -15.0% |
| Operating Income | September 30, 2025 | -$2.09M | +58.6% | +0.9% |
| Gross Profit | September 30, 2013 | $1.11M | -41.8% | +101.2% |
| Shares Outstanding | September 30, 2025 | 13.04M | +28.2% | +28.2% |
- Cocrystal Pharma, Inc. reported Total Revenue of $2.01 million for fiscal year 2020.
- Cocrystal Pharma, Inc. showed a decrease of -69.3% in Total Revenue compared to the prior fiscal year.
- Cocrystal Pharma, Inc. reported Revenue (ASC 606) of $2.01 million for fiscal year 2020.
- Cocrystal Pharma, Inc. showed a decrease of -69.3% in Revenue (ASC 606) compared to the prior fiscal year.
- Cocrystal Pharma, Inc. reported Net Income of -$8.83 million for fiscal year 2025.
- Cocrystal Pharma, Inc. showed an increase of +49.5% in Net Income compared to the prior fiscal year.
- Cocrystal Pharma, Inc. reported Diluted EPS of $0.78 per share (loss) for fiscal year 2025.
- Cocrystal Pharma, Inc. showed an increase of +54.7% in Diluted EPS compared to the prior fiscal year.
- Cocrystal Pharma, Inc. reported Total Assets of $9.71 million for fiscal year 2025.
- Cocrystal Pharma, Inc. showed a decrease of -27.8% in Total Assets compared to the prior fiscal year.
- Cocrystal Pharma, Inc. reported Cash and Equivalents of $26.35 million for fiscal year 2023.
- Cocrystal Pharma, Inc. showed a decrease of -29.1% in Cash and Equivalents compared to the prior fiscal year.
- Cocrystal Pharma, Inc. reported Long-Term Debt of $49.94 million for fiscal year 2015.
- Cocrystal Pharma, Inc. showed a decrease of -23.5% in Long-Term Debt compared to the prior fiscal year.
- Cocrystal Pharma, Inc. reported Stockholders Equity of $6.33 million for fiscal year 2025.
- Cocrystal Pharma, Inc. showed a decrease of -33.5% in Stockholders Equity compared to the prior fiscal year.
- Cocrystal Pharma, Inc. reported R&D Expense of $5.05 million for fiscal year 2025.
- Cocrystal Pharma, Inc. showed a decrease of -59.7% in R&D Expense compared to the prior fiscal year.
- Cocrystal Pharma, Inc. reported Operating Income of -$9.02 million for fiscal year 2025.
- Cocrystal Pharma, Inc. showed an increase of +49.6% in Operating Income compared to the prior fiscal year.
- Cocrystal Pharma, Inc. reported Gross Profit of $7.22 million for fiscal year 2012.
- Cocrystal Pharma, Inc. showed an increase of +168.9% in Gross Profit compared to the prior fiscal year.
- Cocrystal Pharma, Inc. reported Shares Outstanding of 13.78 million shares for fiscal year 2025.
- Cocrystal Pharma, Inc. showed an increase of +35.5% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: